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Abstract Although youth living with behaviorally acquired
HIV (YLWH) are at risk for cognitive impairments, the rela-
tionship of impairments to HIVand potential to improve with
antiretroviral therapy (ART) are unclear. This prospective ob-
servational study was designed to examine the impact of ini-
tiation and timing of ART on neurocognitive functioning in
YLWH in the Adolescent Medicine Trials Network for HIV/
AIDS Interventions. Treatment naïve YLWH age 18–24 com-
pleted baseline and four additional assessments of attention/
working memory, complex executive, and motor functioning
over 3 years. Group 1 co-enrolled in an early ART initiation
study and initiated ART at enrollment CD4 >350 (n=56);
group 2 had CD4 >350 and were not initiating ART (n=66);
group 3 initiated ARTwith CD4 <350 (n=59) per standard of
care treatment guidelines at the time. Treatment was de-
intensified to boosted protease inhibitor monotherapy at
48 weeks for those in group 1 with suppressed viral load.
Covariates included demographic, behavioral, and medical
history variables. Analyses used hierarchical linear modeling.
All groups showed improved performance with peak at
96 weeks in all three functional domains. Trajectories of
change were not significantly associated with treatment,
timing of treatment initiation, or ART de-intensification. De-
mographic variables and comorbidities were associated with
baseline functioning but did not directly interact with change
over time. In conclusion, YLWH showed improvement in
neurocognitive functioning over time that may be related to
practice effects and nonspecific impact of study participation.
Neither improvement nor decline in functioning was associat-
ed with timing of ART initiation or therapy de-intensification.
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Introduction
Recent US guidelines call for all individuals with HIV infec-
tion to initiate antiretroviral therapy (Thompson et al. 2012)
(ART) upon diagnosis, with prevention of central nervous
system (CNS) sequelae serving as one argument for early
initiation (Ellis et al. 2011). Despite ART having diminished
the most severe CNS sequelae of HIV, subtle neurocognitive
impairment continues to be a concern even for those on ART
(Heaton et al. 2011). A meta-analysis found robust but modest
positive effects of ART on HIV-associated cognitive dysfunc-
tion in adults (Al-Khindi et al. 2011). However, few studies
have focused on individuals earlier in infection; while studies
suggest a significant impact of acute HIV infection on the
CNS is due to chronic inflammation that is independent of
viral replication (Ancuta et al. 2008), it could be argued that
control of viral replication by early ARTmay protect the CNS.
Furthermore, late adolescents and young adults (hereafter re-
ferred to as Byouth^) have received less focus in studies of
ART and neurocognition, despite being a population at high
risk for HIV and demonstrating relatively high rates of
neurocognitive impairment (Nichols et al. 2013). Reservations
regarding ART initiation in youth, including poor adherence
resulting in emergence of drug resistant virus and toxicity
associated with long-term treatment (Gagliardo et al. 2013;
Lee et al. 2014), call for studies demonstrating neurocognitive
benefit or at least lack of harm associated with ART in youth.
In 2007, the Adolescent Medicine Trials Network for HIV/
AIDS Interventions (ATN) began enrollment for ATN 061, a
prospective 3-year randomized clinical trial to study the im-
munological impact for youth of initiating highly active anti-
retroviral therapy (HAART) early (CD4+ T cell (CD4) counts
>350 cells/mm3) compared to delaying treatment until concur-
rent treatment guidelines were met. This study also examined
the effect of treatment de-intensification to boosted protease
inhibitor (PI)-monotherapy among participants who achieved
sustained viral suppression. The current study, ATN 071, was
a 3-year prospective observational study designed to assess
changes in neurocognitive functioning associated with early
HAART initiation. The study included ATN 061 participants,
additional untreated youth, and a group initiating ART per
standard of care (SOC). Analysis of baseline data for ATN
071 demonstrated that 66 % of participants qualified for a
diagnosis of HIV-associated neurocognitive disorder
(Antinori et al. 2007) (HAND) at baseline, with impairments
occurring most commonly in memory and learning, executive
functioning, and fine motor speed (Nichols et al. 2013). Sig-
nificant associations of some neurocognitive measures with
CD4 count suggested possible subtle effects of HIV on
neurocognition. Presented herein are longitudinal analyses of
neurocognitive functioning over 3 years to determine whether
ART, timing of ART initiation, and treatment de-
intensification were associated with differences in the
trajectory of neurocognitive functioning over time in ATN
071 while accounting for adherence and important confound-
ing variables. The findings follow up the cohort described in
Nichols et al. 2013 and represent the first study of the impact
of ART on neurocognitive functioning among a key popula-




Youth aged 18–24 years with behaviorally acquired HIV
infection were enrolled from 15 ATN and 5 Internation-
al Maternal Pediatric Adolescent AIDS Clinical Trials
sites across the USA and Puerto Rico. At the time of
enrollment, the US Department of Health and Human
Services Guidelines for the Use of Antiretroviral Agents
in Adults and Adolescents (Guidelines) recommended
starting ART in patients with CD4 cells <350, in ab-
sence of contraindications. Recruitment, participants,
and assessment methodology are described in Nichols
et al. 2013, with essential details repeated herein for
convenience. Participants enrolled into four groups.
Two groups had CD4 >350 at baseline: group 1 partic-
ipants had been randomized to initiate early ART upon
enrollment in ATN 061, while group 2 deferred ART
until SOC guidelines for ART initiation were met.
Group 3 participants met Guidelines for ART initiation
with CD4 <350 at enrollment and started treatment.
Group 4 (CD4 <350 and not initiating ART) was seen
only at baseline and not discussed herein. Participants
co-enrolled in ATN 061 were required to have HIV-1
RNA viral load (VL) >1000 copies/mm3. All partici-
pants were treatment-naïve except for ART to prevent
mother-to-child HIV transmission (PMTCT; n=3) with
total duration of ART <6 months. Fluency in English
or Spanish was required. Exclusion criteria included pri-
or ART experience other than for PMTCT, current preg-
nancy, active substance use judged likely to interfere
with meeting study requirements, psychosis, or signifi-
cant non-HIV-related cognitive or motor impairment
(e.g., cerebral palsy, severe traumatic brain injury;
milder comorbidities including learning disabilities and
attention-deficit/hyperactivity disorder were allowed).
Participants who became pregnant while on study were
discontinued due to potential impact of pregnancy on
treatment considerations and cognition. The study was
approved by Institutional Review Boards at all partici-
pating institutions; participants provided written in-
formed consent in accordance with institutional require-
ments prior to enrollment.
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Study evaluations
Neurocognitive and behavioral functioning Study design
and evaluations are described elsewhere (Nichols et al.
2013). Participants were followed for 144 weeks, completing
study evaluations at baseline and weeks 24, 48, 96, and 144.
The assessment battery included domains with previously
demonstrated sensitivity to HAND in adults (Table 1), includ-
ing memory, motor skills, attention, and complex executive
functions. Standard scores using published normative data,
with adjustments for age and, where available, race, Hispanic
ethnicity, education and/or gender, were computed. Scores
within domains were converted to z-scores and averaged for
analytic clarity and to reduce the number of regression analy-
ses performed. Neurocognitive measures were grouped into
two sets: a monitoring battery conducted at all time points and
a second set of measures administered only at baseline and
exit (Table 1). Analyses reported herein focus on three scales
derived from themonitoring battery reflecting attention, motor
functioning, and complex executive functioning; individual
tests were combined into domain scores to reduce the number
of analyses required (Nichols et al. 2013). The domains
included in the monitoring battery were selected based on
anticipated sensitivity to change (Al-Khindi et al. 2011).
Additional measures of depression, psychiatric distress,
substance use, and medication adherence were administered
for use as covariates in analyses. In addition, participants were
asked whether they use potentially psychoactive substances
(street drugs or medications; PPS), and whether they used
them on the day of testing.
Demographics and psychosocial history Participants report-
ed birth sex, race, ethnicity, primary language, sexual orienta-
tion, employment, school enrollment status, past 30-day in-
come, educational attainment, and educational risk (history of
special education or repeating a grade).
Medical record abstraction Comorbid current and past con-
ditions were rated according to potential impact on current
cognition as none, mild (e.g., headache, adjustment disorder),
moderate (e.g., chronic migraines, major depressive disorder),
or severe (e.g., seizure disorder, skull fracture), following pub-
lished guidelines (Antinori et al. 2007). CD4 and plasma VL
values within 4 weeks preceding the visit, CDC classification
(1992), and date of first positive HIV test were abstracted.
Table 1 Neurocognitive domains and assessment instruments
Domain of functioning Test Name Measure used in analyses
Monitoring battery (entry, wks 24, 48, 96, exit)
Attention/working memory scale Digit Span (WAIS-III; Psychological Corporation 1997) Subtest standard score converted to z-score
Letter-Number Sequencing (WAIS-III) Subtest standard score converted to z-score
Motor/psychomotor scale Digit Symbol (WAIS-III) Subtest standard score converted to z-score
Grooved Pegboard (Strauss et al. 2006) Dominant hand total time z-score
Timed Gait (Robertson et al. 2006) Z-score for average time across 3 trials
Complex executive scale Trailmaking Test (Part B; Reitan and Wolfson 1993;
Mitrushina et al. 2005)
Total completion time z-score
Controlled Oral Word Association (Strauss et al. 2006) F, A, S & Animals total correct z-score
Stroop Test (Interference trial; Norman et al. 2011;
Golden and Freshwater 2002)
Interference trial z-score
Emotional/behavioral covariates Beck Depression Inventory-II (Beck et al. 1987) Total score
Brief Symptom Inventory (Derogatis 1993) Global Severity Index
Alcohol, Smoking and Substance Involvement
Screening Test (World Health Organization 2002)
Risk index for alcohol, marijuana, and
other drugs
Adherence 7-day self-report of percent doses taken
Entry and Exit only
Global functioning WAIS-III 5-subtest IQ estimate Pro-rated IQ estimate derived from
Vocabulary, Similarities, Block Design,
Arithmetic, Matrix Reasoning subtest
Scaled Scores
Learning and Memory Hopkins Verbal Learning Test-R (Norman et al. 2011;
Benedict et al. 1998)
Recognition and Recall corrected T- Scores
Brief Visuospatial Memory Test-R (Norman et al. 2011;
Benedict et al. 1996)
Recognition and Recall corrected T- Scores
WAIS-III Wechsler Adult Intelligenc Scale-Third Edition
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Treatment variables included concomitant medications, ART
initiation, ART regimen, and, for group 1, de-intensification at




Treatment groups were compared using chi-square tests and t
tests.
Modeling
Hierarchical linear modeling (HLM) using software HLM
v7.0 (Raudenbush et al. 2011) was used to analyze the longi-
tudinal neurocognitive scales. All scales (attention, motor, and
complex executive) are expressed in z-score units with mean=
0. HLM accounts for the dependency in observations when
data have a nested, multilevel structure, such as observations
repeated at different times for the same study participant. The
model also incorporates person-level covariates such as demo-
graphic characteristics or baseline clinical values. Included
person-level baseline characteristics were group, gender, age,
race/ethnicity, language spoken, education risk (special edu-
cation class or repeated grade), education level, income earned
in the past 30 days, CD4 count, time since HIV diagnosis, and
viral load. Time-varying covariates included comorbid diag-
nosis rating; Beck Depression Inventory-2 (Beck et al. 1987)
score; Brief Symptom Inventory (Derogatis 1993) score; med-
ications with psychotropic effects; use of alcohol, cannabis,
tobacco, or other drugs; andmedication adherence (7-day self-
report of missed doses). Finally, the model also included terms
for status of anti-retroviral treatment (including early ART
initiation) and ART de-intensification.
Growth curve modeling investigated whether there was
nonlinear change in attention, motor, or complex executive
indices over time. Both linear and quadratic time measures
were included in the model (weeks and weeks2, respectively).
Because of limits on the number of parameters that could be
estimated with five time points and number of random effects,
the linear and quadratic terms for time were estimated over all
participants rather than for each individual. The growth curve
models allowed for testing of group effects, demographic
characteristics, and clinical covariates both as factors affecting
overall neurocognitive performance and as interactions affect-
ing changes over time in neurocognitive performance. Robust
standard errors were used to account for non-normality (Liang
and Zeger 1986). Follow-up analyses examined the effect of
including baseline IQ in models to account for cognitive re-
serve; excluding individuals with severe comorbidities from
models; and modeling treatment effects after grouping partic-
ipants according to ART impact into those who never initiated
ART (n=36), those who initiated ART with consistent viral
suppression across all subsequent time points (n=56), and




Among 182 study participants enrolled between April 2008
and July 2010, baseline data were available for 181 partici-
pants. Participation dropped from 181 at baseline to 171, 151,
139, and 137 at weeks 24, 48, 96, and 144, respectively. At-
trition was significantly higher in group 2 (p<0.005); the most
frequent reason was pregnancy, and participants who
discontinued were significantly more likely than those who
did not to be female (p=0.006). Some individual test data
were eliminated from analyses due to issues with validity
(e.g., long fingernails interfering with fine motor
performance).
Table 2 shows demographic characteristics of study partic-
ipants at baseline. Mean age was 21.0 years. Participants were
predominantly male (80.7 %), non-Hispanic Black/African-
American (65.2 %) or Hispanic (22.7 %), self-identified as
gay or bisexual (71.2 %), and high school educated or beyond
(72.3 %), with 40.8 % currently in school and less than half
(42.6 %) employed. Approximately 21.5 % reported having
repeated a grade, and 22.7 % had received some form of
special education. Nine participants (5 %) reported using a
language other than English at home. Of those, one Spanish-
speaking participant was tested in Spanish; the remainder,
who were bilingual, completed testing in English. Demo-
graphic differences between groups are presented in Table 2.
Clinical HIV characteristics
According to reported dates for first positive HIV test, approx-
imately half the sample had been diagnosed with HIV for less
than a year (Table 3; see Agwu et al. 2012 for discussion of
length of infection in associated ATN 061). Significantly few-
er participants in group 2 (7.6%) had been diagnosed less than
4 months prior to baseline compared with group 1 (25.0 %) or
group 3 (35.6 %) (p=0.0024). Youth with CD4 counts >350 at
baseline accounted for 94.6 % of group 1, 98.5 % of group 2,
and 6.8 % of group 3; inclusion of participants in groups 1 and
2 with CD4 count <350 was due to changes in CD4 between
eligibility screening and baseline assessments. Almost 90 %
overall were in CDC category A, and all but 1.7 % had VL
above 400 copies at baseline; 10.2 % of group 3 had AIDS by
CD4 count <200 at baseline. Baseline VL distribution differed
across the three groups, with 10.7 % of group 1 participants
having VL above 100,000 copies vs. 3.0 % for group 2 and
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Table 2 Demographic and baseline data
Characteristic Group 1 initiating ART
with CD4+ >350
Group 2, CD4+ >350,
not initiating ART




















Baseline 56 100.0 66 100.0 59 100.0 181 100.0 0.0020
Week 24 52 92.9 63 95.5 56 94.9 171 94.5
Week 48 48 85.7 53 80.3 50 84.7 151 83.4
Week 96 48 85.7 45 68.2 46 78.0 139 76.8
Week 144 47 83.9 44 66.7 46 78.0 137 75.7
Age (years) 20.9 1.6 21.2 1.8 20.8 1.9 21.0 1.8 0.5104
Male gender 49 87.5 45 68.2 52 88.1 146 80.7 0.0051
Race/ethnicity 0.7933
Hispanic 11 19.6 18 27.3 12 20.3 41 22.7
Non-Hispanic White 4 7.1 6 9.1 3 5.1 13 7.2
Non-Hispanic Black/African American 38 67.9 38 57.6 42 71.2 118 65.2
Asian/Pacific Islander 2 3.6 2 3.0 0 0.0 4 2.2
Other or mixed race 1 1.8 2 3.0 2 3.4 5 2.8
Language at home 0.4694
English 51 91.1 65 98.5 56 94.9 172 95.0
Spanish 4 7.1 1 1.5 2 3.4 7 3.9
Other 1 1.8 0 0.0 1 1.7 2 1.1
Transgender 2 3.6 3 4.5 4 6.8 9 5.0 0.7661
Sexual orientation 0.0233
Straight (heterosexual) 10 17.9 25 37.9 11 18.6 46 25.4
Gay/lesbian (homosexual) 41 73.2 31 47.0 39 66.1 111 61.3
Bisexual 3 5.4 9 13.6 6 10.2 18 9.9
Not sure/questioning 2 3.6 0 0.0 1 1.7 3 1.7
Refused to answer 0 0.0 1 1.5 2 3.4 3 1.7
Educational status 0.6315
Attending school 19 33.9 19 28.8 20 33.9 58 32.0
GED program 5 8.9 4 6.1 7 11.9 16 8.8
Not currently in school 30 53.6 42 63.6 32 54.2 104 57.5
Other 2 3.6 1 1.5 0 0.0 3 1.7
Level of education 0.8382
Eighth grade or less 2 3.6 1 1.5 2 3.4 5 2.8
Not completed high school 16 28.6 17 25.8 12 20.3 45 24.9
High school graduate 13 23.2 17 25.8 21 35.6 51 28.2
Some education after high school 23 41.1 26 39.4 21 35.6 70 38.7
College graduate 2 3.6 5 7.6 3 5.1 10 5.5
Repeated a grade 14 25.0 10 15.2 15 25.4 39 21.5 0.3041
Special class or education 18 32.1 8 12.1 15 25.4 41 22.7 0.0283
Current employment 0.0098
Full-time 14 25.0 22 33.3 7 11.9 43 23.8
Part-time 5 8.9 13 19.7 16 27.1 34 18.8
Not employed 36 64.3 31 47.0 36 61.0 103 56.9
Refused to answer 1 1.8 0 0.0 0 0.0 1 0.6
Past year income 0.4411
<$6000 39 69.6 38 57.6 44 74.6 121 66.9
$6000–$35,999 15 26.8 25 37.9 15 25.4 55 30.4
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17.6 % for group 3 (p<0.005). ARV regimens were provider
selected except for group 1, who initiated atazanavir/ritonavir
plus tenofovir/emtricitabine as part of ATN 061. Regimens
prescribed for group 3, as well as the subset of group 2 who
subsequently initiated treatment per guidelines, were standard
combinations of protease inhibitors (PI), nucleoside reverse
transcriptase inhibitors (NRTI), non-nucleoside reverse tran-
scriptase inhibitors (NNRTI), and integrase inhibitors (II). Al-
together, 104 study participants used PI-based regimens dur-
ing most or all of study duration, 34 were on NNRTIs, 2 were
on II regimens, and 1 each were on NNRTI/II and PI/II regi-
mens. Thirty-three participants used regimens containing
efavirenz for most or all of study duration; an additional four
used an efavirenz-containing regimen for part of their time on
study. Reported adherence averaged 85 to 90 % over the
course of the study (data not shown). There was a pro-
nounced effect of treatment on both VL and CD4
counts, with VL decreasing and CD4 counts increasing
between entry and week 144 for youth who initiated
treatment (Table 3). Of group 1 participants, 35
underwent treatment de-intensification at week 48 to
atazanavir/ritonavir monotherapy.
Neurocognitive measures over time by group
Figure 1a–c shows descriptive statistics by group for the three
neurocognitive scales over time.
Hierarchical linear modeling
Table 4 shows the results of fitting hierarchical linear models
to the attention, motor, and complex executive scales. All
models contain terms for demographic and clinical covariates,
as well as for change over time.
Attention index The attention index, adjusted for covariates,
increased from 0.161 at baseline to 0.317 at week 96, and then
decreased slightly to 0.263 by week 144. Significantly lower
attention index at baseline was seen in youth who were His-
panic, had education risk, or had comorbid diagnoses with
potentially severe neurocognitive impact (e.g., seizure disor-
der). Other covariates (see BMethods^ section) were not sig-
nificantly associated with the attention scale. Covariates did
not interact significantly with the attention index over time.
Motor index The motor index increased from −1.045 at
baseline to −0.421 at week 96 and then decreased slightly
to −0.553 by week 144. Male youth had significantly
better motor performance than females. Youth with comorbid
diagnoses with potentially severe or moderate neurocognitive
impact had significantly lower mean baseline motor index
than those with mild or no diagnoses. Other covariates were
not significantly associated with the motor scale.
Complex executive index The complex executive index in-
creased from 0.179 at baseline to 0.311 at week 96 and then
decreased to 0.209 by week 144. Baseline executive index
was significantly lower for participants who were older, His-
panic and non-Hispanic Black (vs. non-Hispanic White/oth-
er), had education risk, or had severe potential impact of di-
agnoses. Other covariates were not significantly associated
with the complex executive scale.
Notably, there were no significant differences between
study groups at baseline or in changes over time in the atten-
tion index, motor index, or executive index. Similarly, there
were no observed differences in any index for participants
who de-intensified their ARV medication. Relationships be-
tween covariates and index scores differed by comorbid diag-
nosis impact but did not interact with treatment (Table 4).
Follow-up analyses showed that including baseline IQ as a
covariate, excluding individuals with severe comorbidities, or
grouping participants according to virologic response to ART
did not cause a significant treatment effect on index scores to
Table 2 (continued)
Characteristic Group 1 initiating ART
with CD4+ >350
Group 2, CD4+ >350,
not initiating ART



















Refused to answer 1 1.8 1 1.5 0 0.0 2 1.1
Unknown 1 1.8 2 3.0 0 0.0 3 1.7
Potential impact of comorbid diagnoses
Severe 3 5.4 4 6.1 3 5.1 10 5.5 0.9894
Moderate 17 30.4 24 36.4 20 33.9 59 33.7
Mild 5 8.9 7 10.6 6 10.2 16 10.0
None 31 55.3 31 46.9 30 50.8 89 50.8
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Table 3 Clinical data at baseline and end of study
Characteristic Group 1 >350; starting ART Group 2 >350; ART
monitored per SOC

















Time since HIV diagnosis at entry (months) 0.0024
<4 14 25.0 5 7.6 21 35.6 40 22.1
4–11 18 32.1 17 25.8 19 32.2 54 29.8
12–26 13 23.2 21 31.8 8 13.6 42 23.2
≥27 11 19.6 23 34.8 11 18.6 45 24.9
CDC classification for HIV at entry 0.0564
A 51 91.1 63 95.5 48 81.4 162 89.5
B 5 8.9 3 4.5 10 16.9 18 9.9
C 0 0.0 0 0.0 1 1.7 1 0.6
Viral load
At study entry
<400 0 0.0 2 3.0 1 1.7 3 1.7 0.0049
400 to 10,000 17 30.4 36 54.5 15 25.4 68 37.6
10,001 to 100,000 33 58.9 26 39.4 32 54.2 91 50.3
100,001 to 500,000 5 8.9 2 3.0 10 16.9 17 9.4
>500,000 1 1.8 0 0.0 1 1.7 2 1.1
Mean (std. dev.) 4.3 0.5 3.9 0.6 4.4 0.7 4.2 0.6 0.0001
Median (range) 4.2 3.3–6.1 3.9 2.5–5.1 4.4 2.6–5.9 4.2 2.5–6.1
At end of study
<400 32 68.1 20 45.5 36 78.3 88 64.2 0.0117
400 to 10,000 9 19.1 12 27.3 3 6.5 24 17.5
10,001 to 100,000 6 12.8 10 22.7 7 15.2 23 16.8
100,001 to 500,000 0 0 2 4.5 0 0 2 1.5
>500,000 0 0 0 0 0 0 0 0.0
Meanlog10 units (std. dev.) 3.1 1.1 3.8 1.0 3.9 0.9 3.6 1.0 0.0631
Median (range) 3.4 1.4–4.7 3.9 1.6–5.7 4.2 2.1–5.0 4.0 1.4–5.7
CD4+ count
At study entry
<200 0 0.0 0 0.0 6 10.2 6 3.3 <0.0001
200 to 349 3 5.4 1 1.5 49 83.1 53 29.3
350 to 499 24 42.9 26 39.4 4 6.8 54 29.8
≥500 29 51.8 39 59.1 0 0.0 68 37.6
Mean (std. dev.) 552.4 188.4 595.6 200.6 275.7 79.0 478.0 218.1 <0.0001
Median (range) 506.5 280–1167 533.0 300–1160 288.0 16–498 440.0 16–1167
At end of study
<200 0 0.0 3 6.8 0 0 3 2.2 0.0025
200 to 349 3 6.4 4 9.1 9 19.6 16 11.7
350 to 499 2 4.3 5 11.4 9 19.6 16 11.7
≥500 42 89.4 31 70.5 25 54.3 98 71.5
Mean (std. dev.) 808.8 278.6 584.5 225.5 556.1 212.6 654.6 266.2 0.0168
Median (range) 789.0 227–1476 604.0 80–1076 536.0 205–1067 651.0 80–1476
CD4+ percent
At study entry
<15 % 3 5.4 0 0.0 18 30.5 21 11.6 <0.0001
15 to 24 % 17 30.4 23 34.8 37 62.7 77 42.5
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emerge. Higher full-scale IQ at baseline was associated with
higher index scores at baseline and greater improvement in
motor/psychomotor index scores over time, but the inclusion
of IQ inmodels of group effects did not alter treatment findings.
Discussion
This paper reports findings from the first prospective observa-
tional study of neurocognitive functioning in YLWH initiating
ART at different CD4 thresholds. Models of trajectories of
neurocognitive functioning over 3 years were examined for
both positive and negative change. A broad neurocognitive,
behavioral, demographic, and health history database allowed
for the evaluation of several cognitive domains and multiple
potential confounding factors. The key finding is that all three
cognitive functional domains considered here improved sig-
nificantly over time, each peaking at about 96 weeks into the
study. Some degree of positive change was anticipated due to
the likelihood of practice effects for neurocognitive measures
(Duff 2012; Woods et al. 2006); our analytic approach was
designed to compare the magnitude of change across groups.
However, while there were modifying effects of demographic
characteristics and non-HIV medical diagnoses, the magnitude
and direction of change were not associated with treatment
group or with clinical indicators of HIV-related disease factors.
In addition, there were no differences associatedwith treatment
de-intensification following viral suppression among early-
treated youth, supporting safety of this management approach.
Prior studies with adults have found that ART is associated
with modest improvements in cognitive functioning overall
and that these improvements are seen largely in the areas of
attentional, motor, and executive functioning (Al-Khindi et al.
2011). The sensitivity of these functional domains to HIV as
well as to ART was the reason they were chosen for longitu-
dinal monitoring in youth in the study reported here. The
measures selected were ones that had a well-established track
record in the adult HIV literature. The significant associations
of the neurocognitive measures with other risk factors for the
participants, such as educational risk and comorbid diagnoses,
were in the predicted directions, suggesting that the lack of
significant treatment effects was not likely due to insensitivity
of the measures. Further support for measurement sensitivity
comes from baseline findings showing subtle associations of
some cognitive variables with CD4 count (Nichols et al.
2013). Nevertheless, treatment effects were not detected for
our groups of youth with behaviorally acquired HIV.
There are several possible reasons that we did not observe
effects of ART on cognitive functioning. One possibility is
that, despite concern raised by the baseline findings regarding
HIV impact on the CNS even in our relatively healthy cohort
of youth, the contribution of HIV to neurocognitive function-
ing in our complex cohort is small enough relative to other
influences and comorbidities that improvements with ART
were too subtle to be detected with our sample size. A second
possible explanation is that the medications did not adequately
penetrate the central nervous system; a relatively narrow range
of penetrance was represented and regimens for the most part
were not highly penetrant (data not shown). A third possibility
that could be raised is that participants were not adhering to
their medications; however, reported adherence was reason-
ably good overall, supported by changes in CD4 and viral
load, adherence was included as a covariate in analyses, and
analyzing data according to virologic ART response did not
alter the findings. Fourth, it may be that the observed impair-
ments are related to persistent immune activation and inflam-
mation established early in infection that is not reversed by
ART (Ancuta et al. 2008; Wallet et al. 2010). Data collected
Table 3 (continued)
Characteristic Group 1 >350; starting ART Group 2 >350; ART
monitored per SOC

















>24 % 36 64.3 43 65.2 4 6.8 83 45.9
Mean (std. dev.) 27.2 7.1 28.3 8.2 17.5 6.2 23.8 8.7 <0.0001
Median (range) 28.4 13–40 28.1 15–50 18.0 1–34 23.8 1–50
At end of study
<15 % 4 8.5 5 11.4 2 4.3 11 8.0 0.4513
15 to 24 % 2 4.3 4 9.1 6 13 12 8.8
>24 % 41 87.2 34 77.3 35 76.1 110 80.3
Mean (std. dev.) 35.5 10.3 30.7 11.4 31.4 9.0 32.6 10.4 0.0168
Median (range) 38.0 10–53 32.0 0.3–52 31.0 7.5–50 34.0 0.3–53.0
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Table 4 Hierarchical linear model for attention, motor and complex executive scales
HLM terms Coefficient Std. error p value
Attention scale
Model for baseline intercept
Intercept 0.161 0.175 0.358
Hispanic (vs. non-Hispanic white and other) −0.412 0.193 0.034
Non-Hispanic Black (vs. non-Hispanic white and other) −0.349 0.178 0.052
Education risk (special class or repeated grade) −0.427 0.106 <.001
Model for change over time
Linear term 0.083 0.023 <.001
Quadratic term −0.011 0.004 0.005
Effect of diagnoses with severe potential impact
Intercept −0.234 0.119 0.051
Baseline viral load 0.543 0.144 <.001
Effect of diagnoses with moderate potential impact
Intercept 0.097 0.053 0.072
Baseline viral load 0.080 0.049 0.102
Motor Scale
Model for baseline intercept
Intercept −1.045 0.153 <.001
Male gender 0.481 0.168 0.005
Model for change over time
Linear term 0.304 0.027 <.001
Quadratic term −0.037 0.004 <.001
Effect of diagnoses with severe potential impact
Intercept −1.670 0.195 <.001
Male gender 1.257 0.243 <.001
Effect of diagnoses with moderate potential impact
Intercept −0.474 0.244 0.053
Male gender 0.440 0.259 0.092
Complex executive scale
Model for baseline intercept
Intercept 0.179 0.127 0.161
Age −0.081 0.033 0.016
Hispanic (vs. non-Hispanic White and other) −0.575 0.138 <.001
Non-Hispanic Black (vs. non-Hispanic White and other) −0.472 0.126 <.001
Education risk (special class or repeated grade) −0.349 0.096 <.001
Model for change over time
Linear term 0.089 0.025 <.001
Quadratic term −0.014 0.004 0.001
Effect of diagnoses with severe potential impact
Intercept −1.640 0.119 <.001
Age 0.074 0.039 0.061
Male gender 1.529 0.121 <.001
CD4 at baseline 0.154 0.021 <.001
Viral load at baseline 0.702 0.068 <.001
Effect of diagnoses with moderate potential impact
Intercept −0.227 0.148 0.127
Age −0.135 0.035 <.001
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from ATN 061 have demonstrated that T cell activation de-
creases with treatment but does not approach that of uninfect-
ed adolescents. In addition, ATN 061 demonstrated that, even
with early initiation of ART, inflammatory markers including
sCD14, sCD163, and sCD27 began and remained significant-
ly higher than among a cohort of uninfected comparison youth
similar in age, race, and substance use to the ATN 061 cohort
(Rudy et al. 2014). An additional possibility is that the impair-
ments seen at baseline were not related to HIV and that the
CD4 findings were spurious. Rigorous measures were taken to
account for other influences on neurocognitive functioning
(Nichols et al. 2013), and exclusion of individuals with the
most severe comorbidities did not affect the findings, but it
should be acknowledged that controversy exists regarding the
specificity of mild, asymptomatic neurocognitive impairments
in adults with HIV disease (Gisslen et al. 2011; Grant et al.
2014; McDonnell et al. 2014). Further studies are needed to
explore the impact of ART in the context of treatment begun in
acute infection, using additional CNS measures such as neu-
roimaging, to evaluate regimens with a wider range of CNS
penetrance, and to examine longitudinal associations with bio-
markers of immune activation and inflammation.
With changes in US treatment guidelines, which now rec-
ommend ART in all HIV-infected persons regardless of im-
mune function, evaluation of potential neurotoxicity of regi-
mens has assumed greater importance. Particularly for young,
asymptomatic individuals facing a lifetime of ART, concern
about potential negative impacts of ART on functioning may
decrease willingness to initiate or adhere to treatment. It is
noteworthy that our findings indicated similar neurocognitive
improvement in participants regardless of ART, suggesting
lack of a negative impact of ART in general. Exploratory
analyses including efavirenz, a medication that has been asso-
ciated with CNS toxicity (Ciccarelli et al. 2011; Decloedt and
Maartens 2013), did not find a differential effect on
neurocognitive functioning. However, the number of youth
taking this medication was small. Further studies are needed
to support the safety of early ART in youth.
As noted in our description of baseline findings from ATN
071 (Nichols et al. 2013), a high percentage of youth in our
cohort demonstrated neurocognitive impairment. Important
questions remain for future studies, particularly if further stud-
ies continue to show that these impairments do not improve
with ART. The origin of impairments may include modifiable
factors such as substance use that could be the target of
preventive interventions. Potential interventions could also
include cognitive remediation, lifestyle modification such as
exercise, as well as provision of enhanced education for
healthcare-related and other daily living tasks for youth with
impairment(s). Youth with the most significant impairments
may be at risk for poor adherence, potentially leading to cog-
nitive decline as part of disease progression (Ettenhofer et al.
2010); cognitive screening could be used to select youth for
more intensive adherence support. The potential impact of
impairments on other HIV prevention efforts, such as effec-
tiveness of risk behavior reduction interventions, has public
health implications and merits further research. Finally, long-
term studies are needed to determine whether YLWH who
have cognitive impairments are more vulnerable to cognitive
decline associated with other risks such as head injury or ag-
ing. Exploratory analyses of our data demonstrated that
neurocognitive impairment at baseline was associated
with differences in trajectory of change, a finding that
will be explored further in subsequent publications;
however, it should be noted that inclusion of baseline
cognitive performance or HAND diagnosis did not alter
the finding of no treatment effects.
This study has several limitations. A primary limita-
tion is that, while a portion of the participants with CD4
>350 were randomized to treatment or no treatment, the
study as a whole was not a randomized clinical trial. In
fact, treatment guidelines to initiate ART following HIV
diagnosis preclude randomized studies comparing treated
and untreated YLWH. Differences between the three
study groups in some characteristics other than CD4 at
baseline may have contributed to lack of a treatment
effect and limit conclusions that can be drawn. However,
it should be noted that analyses considered these charac-
teristics as well as other variables. An additional limita-
tion was the lack of an uninfected control group which
could address nonspecific effects such as practice and
possible developmental changes over time (however,
age-standardized scores were used to account for devel-
opment). Future studies should follow a well-matched
uninfected group of youth to help account for these ef-
fects. Measurement of nonspecific clinical effects of par-
ticipation, such as more frequent interaction with the
clinic team, may also partially explain the non-ART-
related positive change. Measures of memory and learn-
ing were included only at baseline and week 144 and
Table 4 (continued)
HLM terms Coefficient Std. error p value
Male gender 0.377 0.160 0.020
CD4 at baseline 0.033 0.024 0.177
Viral load at baseline −0.014 0.066 0.835
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Fig. 1 Descriptive statistics by
group for a attention, b motor,
and c complex executive scales
over time
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were not included in these analyses; however, explorato-
ry analyses demonstrated no associations of treatment
with change in these measures. Although a significant
number of youth were recently diagnosed with HIV, the
study did not focus on youth with acute infection, a
group likely to be most impacted by changes in treat-
ment guidelines. Follow-up continued for 3 years, which
may not have been protracted enough to observe longer
term impacts of HIV and ART in youth. Finally, sample
sizes were small for evaluation of some effects such as
treatment de-intensification.
In conclusion, despite evidence of significant impairment
at baseline, youth with behaviorally acquired HIV showed
modest positive changes in neurocognitive functioning over
3 years of follow-up that were not related to antiretroviral
treatment. Further research is needed to evaluate the impact
of earlier treatment, newer regimens, and those with greater
CNS penetrance.
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